Breaks Categories: Analyst Alerts

WednesdayOct 04, 2017 11:48 am

NetworkNewsBreaks – SeeThruEquity Updates Coverage on Apricus Biosciences, Inc. (NASDAQ: APRI)

SeeThruEquity issued a company update and price target of $4.30 on shares of Apricus Biosciences, Inc.’s (NASDAQ: APRI) stock. The analyst noted that the company has several upcoming catalysts, including the FDA decision for its Vitaros™ New Drug Application (NDA) resubmission. The company has already received its PDUFA date, which is February 17, 2018. If approved, Vitaros™ could be commercialized in the multi-billion-dollar erectile dysfunction (ED) market by the end of 2018. For more information, visit www.Apricusbio.com About Apricus Biosciences, Inc. Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product…

Continue Reading

TuesdayOct 03, 2017 3:24 pm

NetworkNewsBreaks – Mizuho Securities Reiterates ‘Buy’ Rating, Raises PT on Zogenix, Inc. (NASDAQ: ZGNX)

Mizuho Securities USA LLC has reiterated its ‘Buy’ rating and raised its price target from $28.00 to $51.00 on shares of Zogenix, Inc.’s (NASDAQ: ZGNX) stock. The report follows the company’s release of positive topline data for its pivotal phase 3 trial of ZX008 in Dravet Syndrome - Study 1. The study reached its primary endpoint, representing that 0.8 mg/kg/day of ZX008 as an adjunctive therapy is greater than a placebo in reducing mean monthly convulsive seizure frequency. The results also validate ZX008s mechanism of action involving Sig-1R receptor. The analyst noted that the efficacy results are better than expected,…

Continue Reading

MondayOct 02, 2017 11:53 am

NetworkNewsBreaks – Mizuho Securities Reiterates “Buy” Rating on Aerie Pharmaceuticals, Inc. (NASDAQ: AERI)

Mizuho Securities USA LLC has reiterated its ‘Buy’ rating and price target of $70 on shares of Aerie Pharmaceuticals, Inc.’s (NASDAQ: AERI) stock after a Mizuho analyst spoke with company management regarding recent updates. Aerie’s shares have been weak since the company announced that its FDA advisory committee meeting on Rhopressa is scheduled for October 20. The analyst believes the weak shares represent a buying opportunity for investors. Additionally, the analysts noted that they believe the majority of the discussion at the meeting with the FDA on Rhopressa will be regarding potential side effects rather than efficacy. For more information,…

Continue Reading

FridaySep 29, 2017 2:38 pm

NetworkNewsBreaks – Zogenix, Inc. (NASDAQ: ZGNX) Shares Soar on Positive Phase 3 Trial of ZX008; Reaffirmed with ‘Buy’ Rating at Mizuho

Shares of Zogenix, Inc. (NASDAQ: ZGNX) clipped a new 52-week high earlier today after the company said its ZX008 for Dravet Syndrome (DS) met its primary endpoint in a phase 3 trial. ZX008 is designated as an orphan drug in both the U.S. and Europe, and it has received Fast Track designation in the U.S. for the treatment of DS. “On behalf of everyone at Zogenix, I would like to extend my sincere appreciation to the patients, families and investigators involved in this study. We are extremely pleased with the top-line efficacy and safety results from Study 1 which reinforce the…

Continue Reading

FridaySep 29, 2017 12:00 pm

NetworkNewsBreaks – Mizuho Securities Reiterates ‘Buy’ Rating on Achaogen, Inc. (NASDAQ: AKAO)

Mizuho Securities USA LLC has reiterated its ‘Buy’ rating and price target of $28 on shares of Achaogen, Inc.’s (NASDAQ: AKAO) stock after the company yesterday said that it has been awarded a contract valued at up to $18 million in funding from the Biomedical Advanced Research and Development Authority (BARDA). The funding will support the development of C-Scape, Achaogen’s product candidate being developed to treat serious bacterial infections due to extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. The BARDA contract comprises of $12 million of funding through a nine-month base period and additional option periods worth around $6 million. The analyst…

Continue Reading

WednesdaySep 27, 2017 12:34 pm

NetworkNewsBreaks – Mizuho: ViewRay, Inc. (NASDAQ: VRAY) Technology Topic of Discussion in Upcoming Industry Expert Conference Call

ViewRay (NASDAQ: VRAY) was recently covered in a U.S. Equity Research report by Mizuho Securities USA LLC. The company was issued a 'Buy' rating and price target of $12 per share. The company's technology will be part of an "Industry Expert Conference Call" taking place October 17 at 11 a.m. ET. The call will discuss "MRI guided LINAC – ViewRay’s MRidian or Elekta’s Unity?” Among others, a few topics to be covered include why MRI-LINAC is needed for radiation oncology, the decision-making process at Washington University in choosing ViewRay’s MRIdian and other relevant clinical experience. To view the full report,…

Continue Reading

WednesdaySep 27, 2017 12:03 pm

NetworkNewsBreaks – SeeThruEquity Updates Coverage on Net Element, Inc. (NASDAQ: NETE)

SeeThruEquity updated coverage on Net Element, Inc. (NASDAQ: NETE) this week following release of the company’s earnings report for the second quarter of 2017. Net Element reported second quarter revenue of $16.1 million, representing an 18% increase from the second quarter of 2016. The analyst noted that this impressive performance was primarily attributed to the company’s NA Transactions segment, which saw revenue growth of 31% YoY. The company’s Online Solutions segment also displayed hearty growth from a small base with a revenue increase of 33% YoY. Additionally, the analyst noted that the company has been given until October 20, 2017,…

Continue Reading

WednesdaySep 27, 2017 12:00 pm

NetworkNewsBreaks – Mizuho Securities Initiates Coverage with ‘Buy’ Rating on Heron Therapeutics, Inc. (NASDAQ: HRTX)

Mizuho Securities USA LLC has initiated coverage with a ‘Buy’ rating and price target of $28 on shares of Heron Therapeutics, Inc.’s (NASDAQ: HRTX) stock. The company currently has two drugs in development in the chemotherapy-induced nausea and vomiting (CINV) space. Its lead product, Sustol, is in the commercial stage, while Cinvanti is up for approval in November 2017. Heron expects to launch Cinvanti in the first quarter of 2018. The analyst believes that the company’s potential to have two CINV drugs targeting two sides of a $900 million market is underappreciated and predicts that Heron will reach break-even in…

Continue Reading

WednesdaySep 27, 2017 11:59 am

NetworkNewsBreaks – Nektar Therapeutics (NASDAQ: NKTR) Receives ‘Buy’ Rating from Mizuho Securities

Mizuho Securities USA LLC has initiated coverage with a ‘Buy’ rating and price target of $30 on shares of Nektar Therapeutics’ (NASDAQ: NKTR) stock. Mizuho analysts believe Nektar’s immuno-oncology candidate NKTR-214 is the company’s most valuable asset, as it could provide significant upside while the company’s royalty-generating portfolio maintains a more consistent revenue stream for the biotech company. Additionally, Nektar has formed collaborations with numerous pharmaceutical companies on its PEGylation platform, which also provides a predictable revenue stream and a stable foundation. For more information, visit www.Nektar.com About Nektar Nektar Therapeutics is a research-based development stage biopharmaceutical company with a…

Continue Reading

TuesdaySep 26, 2017 12:26 pm

NetworkNewsBreaks – Mizuho Securities Reiterates ‘Buy’ Rating on ViewRay, Inc. (NASDAQ: VRAY)

Mizuho Securities USA LLC has reiterated its ‘Buy’ rating and price target of $12 on shares of ViewRay, Inc.’s (NASDAQ: VRAY) stock following a meeting the company held in San Diego on Monday during the annual meeting of the American Society for Radiation Oncology (ASTRO). The analyst noted that ViewRay reaffirmed its 2017 full-year revenue guidance of $45-50 million. The affirmation by the company reassures the analyst’s prediction that the company is on track to possibly reach break-even by the end of 2018. During the meeting, the company also provided an update regarding the MRIdian. Among other highlights, the data…

Continue Reading